Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jan 29:8:31.
doi: 10.1186/1471-2407-8-31.

The impact of comorbidity and stage on ovarian cancer mortality: a nationwide Danish cohort study

Mette S Tetsche  1 , Claus Dethlefsen, Lars Pedersen, Henrik T Sorensen, Mette Norgaard
Affiliations

The impact of comorbidity and stage on ovarian cancer mortality: a nationwide Danish cohort study

Mette S Tetsche et al. BMC Cancer. .

Abstract

Background: The incidence of ovarian cancer increases sharply with age, and many elderly patients have coexisting diseases. If patients with comorbidities are diagnosed with advanced stages, this would explain the poor survival observed among ovarian cancer patients with severe comorbidity. Our aims were to examine the prevalence of comorbidity according to stage of cancer at diagnosis, to estimate the impact of comorbidity on survival, and to examine whether the impact of comorbidity on survival varies by stage.

Methods: From the Danish Cancer Registry we identified 5,213 patients (> 15 years old) with ovarian cancer diagnosed from 1995 to 2003. We obtained information on comorbidities from the Danish National Hospital Discharge Registry. Vital status was determined through linkage to the Civil Registration System. We estimated the prevalence of comorbidity by stage and computed absolute survival and relative mortality rate ratios (MRRs) by comorbidity level (Charlson Index score 0, 1-2, 3+), using patients with Charlson Index score 0 as the reference group. We then stratified by stage and computed the absolute survival and MRRs according to comorbidity level, using patients with Charlson score 0 and localized tumour/FIGO I as the reference group. We adjusted for age and calendar time.

Results: Comorbidity was more common among patients with an advanced stage of cancer. One- and five-year survival was higher in patients without comorbidity than in patients with registered comorbidity. After adjustment for age and calendar time, one-year MRRs declined from 1.8 to 1.4 and from 2.7 to 2.0, for patients with Charlson scores 1-2 and 3+, respectively. After adjustment for stage, the MRRs further declined to 1.3 and 1.8, respectively. Five-year MRRs declined similarly after adjustment for age, calendar time, and stage. The impact of severe comorbidity on mortality varied by stage, particularly among patients with tumours with regional spread/FIGO-stages II and III.

Conclusion: The presence of severe comorbidity was associated with an advanced stage of ovarian cancer. Mortality was higher among patients with comorbidities and the impact of comorbidity varied by stage.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier survival curves for ovarian cancer patients with localized tumour/FIGO stage I, according to presence of comorbidity at time of diagnosis.
Figure 2
Figure 2
Kaplan-Meier survival curves for ovarian cancer patients with regional spread/FIGO stage II and III, according to presence of comorbidity at time of diagnosis.
Figure 3
Figure 3
Kaplan-Meier survival curves for ovarian cancer patients with distant metastases/FIGO stage IV, according to presence of comorbidity at time of diagnosis.
See this image and copyright information in PMC

References

    1. Sant M, Aareleid T, Berrino F, Bielska LM, Carli PM, Faivre J, Grosclaude P, Hedelin G, Matsuda T, Moller H, Moller T, Verdecchia A, Capocaccia R, Gatta G, Micheli A, Santaquilani M, Roazzi P, Lisi D. EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary. Ann Oncol. 2003;14 Suppl 5:v61–118. doi: 10.1093/annonc/mdg754. - DOI - PubMed
    1. Janssen-Heijnen ML, Houterman S, Lemmens VE, Louwman MW, Coebergh JW. Age and co-morbidity in cancer patients: a population-based approach. Cancer Treat Res. 2005;124:89–107. - PubMed
    1. Sharma S, Driscoll D, Odunsi K, Venkatadri A, Lele S. Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients. Am J Obstet Gynecol. 2005;193:2077–2082. doi: 10.1016/j.ajog.2005.06.074. - DOI - PubMed
    1. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity. a critical review of available methods. J Clin Epidemiol. 2003;56:221–229. doi: 10.1016/S0895-4356(02)00585-1. - DOI - PubMed
    1. West DW, Satariano WA, Ragland DR, Hiatt RA. Comorbidity and breast cancer survival: a comparison between black and white women. Ann Epidemiol. 1996;6:413–419. doi: 10.1016/S1047-2797(96)00096-8. - DOI - PubMed

Publication types

MeSH terms